The complete GLP-1 cost guide (2026): every price, every path

GLP-1 pricing in 2026 is a moving target, and the single number you see in a headline almost never matches what you pay. The list price, the insurance copay, the manufacturer self-pay rate, and the telehealth bundle are four different numbers for the same molecule. This guide maps all of them so you can find the cheapest legitimate path for your situation.

List prices: the number nobody actually pays

Branded GLP-1 list prices in 2026 sit around $1,300-1,350/month for Wegovy and roughly $1,000-1,080/month for Zepbound, regardless of dose. Ozempic and Mounjaro (the type-2-diabetes labels of the same molecules) list slightly lower. Almost no one pays these numbers. They matter only as the ceiling against which every discount is measured.

Path 1: Insurance with coverage

If your plan covers GLP-1s for weight loss outright, your copay is typically $25-100/month, and a manufacturer commercial-insurance savings card can drop it toward $0-25. This is by far the cheapest path. The catch: many employer plans exclude weight-loss drugs entirely even when they cover the same molecule for diabetes.

If your plan requires prior authorization, expect $25-150/month after approval, but the approval itself can take weeks and may be denied. Programs with an insurance concierge (Ro is the clearest example) file the PA for you, which is the single biggest reason to pay for a clinical-leaning program over a bare cash-pay one.

Path 2: Manufacturer direct-pay (the new floor for branded)

Both manufacturers now sell direct to cash-pay patients. NovoCare self-pay offers Wegovy from about $499/month. LillyDirect sells Zepbound vials from $349-549/month and is launching orforglipron, its new oral pill, at $149/month. These channels still route the prescription through a clinician, but they bypass the pharmacy and PBM markup. For a cash-pay patient who wants the branded drug, direct-pay is now the price floor.

Run the numbers for your situation

Plug your candidate monthly cost and a treatment horizon (6 months is a common decision frame) and compare against retail. The calculator updates the total and the relative saving against retail in real time.

Path 3: Telehealth bundles

Telehealth programs bundle the consult, prescription, and support into a monthly rate. Branded telehealth runs roughly $199-599/month depending on what's included; flat-rate programs (Henry Meds) avoid the intro-to-renewal cliff that catches buyers on subscription models. Watch for the membership-plus-medication split: a $79/month membership on top of the drug is a different total than a $297 flat rate.

Path 4: Compounded (ending in 2026)

Compounded semaglutide and tirzepatide once ran $150-400/month and were the affordability story of 2023-2024. That era is closing: the FDA proposed permanently ending mass compounding on April 30, 2026, and large platforms have exited. If you're on a compounded program, treat it as temporary and plan a transition to a direct-pay or insurance path.

How a savings card actually works (a where it doesn't)

The Wegovy and Zepbound manufacturer savings cards are the lever that drops insurance copays toward $0-25 for eligible patients. They are also the most misread benefit in this category — readers assume they apply to anyone with insurance and get blindsided at the pharmacy [1][2].

Hard eligibility rules. Commercial insurance only — Medicare, Medicaid, TRICARE, and the VA are excluded by federal anti-kickback statute. Showing a Medicare card at the pharmacy nullifies the savings card automatically. The cards also cap dollar value per fill and per year (Novo: up to $225 per 28-day fill, $1,800/year; Lilly: similar order of magnitude), so patients on the full list-price path still pay above $0 once the cap is hit.

How it stacks with insurance. The card is a secondary benefit that runs after the primary insurance copay calculation. If your plan covers Wegovy with a $50 copay, the card can bring that to $25; if your plan denies coverage outright, the card cannot turn a denial into a fill. This is the most common misunderstanding — savings cards reduce a paid copay, they don't substitute for coverage.

How it interacts with deductibles. On high-deductible plans, the savings card pays toward your out-of-pocket maximum only if your plan allows manufacturer assistance to count (some don't, via 'copay accumulator' programs). Check the plan document before assuming the card draws down your deductible — getting this wrong is a four-figure surprise at the next medical claim.

Reading a manufacturer direct-pay program

NovoCare and LillyDirect are the manufacturers' answer to the 30%+ of weight-management patients with no commercial coverage. The economics differ from a traditional cash-pay prescription, and the eligibility fine print matters [3][4].

NovoCare Wegovy at ~$499/month covers the medication only. The prescription still has to come from a clinician; the program routes patients to either their existing prescriber or a tele-prescribing partner. Patients without commercial insurance pay $499; patients with commercial insurance that excludes weight-loss drugs may also qualify — there is no income test, but it is a self-pay program by design.

LillyDirect Zepbound vials run $349-549/month depending on dose; LillyDirect orforglipron will launch at $149/month. The vials are single-dose, room-temperature-stable units shipped directly. The trade-off vs the pen: lower price, manual injection workflow.

Both programs exclude patients with insurance coverage that would pay (you cannot stack direct-pay over a covered plan). If you have coverage, run that path; direct-pay is the floor for people who do not.

Telehealth bundles: where the money actually goes

Telehealth GLP-1 bundles are the most variable line item on this page and the easiest to misread. Three patterns generate most of the confusion [5].

Membership-plus-medication. A program advertises 'from $79/month' on a banner and the $79 is the membership; the medication is a separate per-month charge. Total real cost can be $79 + $349 (LillyDirect-pass-through) = $428/month. Always sum the two before comparing to a flat-rate program.

Intro-to-renewal cliff. Many programs sell heavily discounted first-month or first-three-month rates that rise sharply on auto-renewal. A $99 intro that renews at $349 is a $250 jump. This is the most predictable affordability shock; programs that lead with flat rates (Henry Meds is the clearest example) skip it entirely.

Compounded vs branded mid-flight. Some programs started patients on compounded semaglutide at $200-300/month and are switching new patients to branded at $400-500/month as compounding ends. Existing patients may or may not be grandfathered; ask before signing up.

When a coverage denial is worth appealing

Roughly 40-60% of initial GLP-1 prior authorizations for weight loss are denied by commercial plans [6]. About one-third of denials are reversed on first-level appeal when the appeal is well-structured.

What makes an appeal worth filing. Documented BMI in the qualifying range (typically ≥30, or ≥27 with comorbidity), prior failed lifestyle interventions on record, and at least one qualifying comorbidity (hypertension, dyslipidemia, prediabetes, sleep apnea). If three of those are documented in chart notes, the appeal usually clears.

Mechanically: request a formulary exception via your plan's published process within the appeal window (typically 60 days from denial). The exception letter cites your specific criteria; programs with insurance concierges write these as a service. If self-filing, your prescriber must include a letter of medical necessity referencing the indicated label.

When not to appeal. If your plan explicitly excludes the entire weight-management drug class as a benefit category (read the Summary of Benefits), no appeal will overturn that — it is a plan design decision, not a coverage interpretation. Switching plans at the next open enrollment is the actual lever there.

International ordering: legal status and risks

Patients facing $500-1,300/month cash prices sometimes consider ordering GLP-1 medications from Canadian, Mexican, or overseas pharmacies. The legal and safety picture is more constrained than the marketing of those services suggests [7].

Personal importation under the FDA's compliance policy is a narrow exception: small quantity, for personal use, for a serious condition where comparable treatment is unavailable in the US. Wegovy and Zepbound are both available in the US through legitimate channels — that fact alone makes personal importation outside the policy.

Beyond legality, the safety floor matters. Counterfeit semaglutide has been documented in non-US channels, with insufficient labeling, wrong concentrations, and bulk semaglutide sodium being substituted for the prescribed peptide. The FDA has issued specific warnings on this product class [7].

If cost is the constraint, the legitimate cheaper paths are insurance plus savings card, manufacturer direct-pay, or oral options like orforglipron at $149/month — not unverifiable overseas pharmacies.

The decision in one line

If insurance covers it, use insurance and add the savings card. If not, compare manufacturer direct-pay against a flat-rate telehealth bundle, and weigh orforglipron's $149 oral option if you'd prefer no injection. Use our cost estimator to see your specific paths, and our cheapest-programs ranking for current telehealth pricing.